| 201 | 0 | 57 |
| 下载次数 | 被引频次 | 阅读次数 |
代谢相关脂肪性肝病（MAFLD）是全球性健康问题，患病人群庞大，目前治疗手段有限。中医药以整体观念与辨证论治为核心，实施个体化干预，其多靶点、多途径调控特点与MAFLD复杂发病机制高度契合。黄连-黄芩药对相须为用，功善清热燥湿、泻火解毒；入复方配伍后，其整体功效随组方加减发生演变，在MAFLD防治中呈现出多靶点、整体调控的优势，关键活性成分包括黄连素、黄芩苷、黄芩素、汉黄芩苷、汉黄芩素等。本文系统梳理相关研究进展，证实该药对及活性成分可通过调节脂代谢、改善线粒体功能障碍、抗氧化应激、抗内质网应激、抗炎、调控肠-肝轴、调控自噬、抗凋亡及抗纤维化等多通路干预MAFLD进程，展现出显著的药理活性与临床转化潜力。黄连-黄芩药对入复方配伍后，依组方配伍规律，在清热燥湿基础上可调和寒热、疏利枢机、健脾和胃、化痰祛湿。本文全面综述黄连-黄芩活性成分及其配伍复方防治MAFLD的研究进展，旨在为其深入机制探讨、临床合理应用及新药研发提供科学依据。
Abstract：Metabolic-associated fatty liver disease (MAFLD) is a global health problem affecting a large population， with limited therapeutic options currently available. Traditional Chinese medicine (TCM)， centered on the holistic concept and treatment based on syndrome differentiation， implements individualized interventions. Its multi-target and multi-pathway regulatory characteristics are highly consistent with the complex pathogenesis of MAFLD. The COPTIDIS RHIZOMA and SCUTELLARIAE RADIX herb pair exerts synergistic effects and is effective in clear heat， dry dampness， purge fire and detoxify. When incorporated into compound formulas， its overall effects evolve with modifications in formula composition， demonstrating the advantages of multi-target and holistic regulation in the prevention and treatment of MAFLD. Key active components include berberine， baicalin， baicalein， wogonoside， and wogonin. This paper systematically reviews the relevant research progress and confirms that the herb pair and its active components can intervene in the progression of MAFLD through multiple pathways， including regulating lipid metabolism， improving mitochondrial dysfunction， combating oxidative stress， alleviating endoplasmic reticulum stress， exerting anti-inflammatory effects， modulating the gut–liver axis， regulating autophagy， inhibiting apoptosis， and preventing fibrosis， thereby demonstrating significant pharmacological activity and potential for clinical translation. After incorporation into compound formulas， the COPTIDIS RHIZOMA and SCUTELLARIAE RADIX herb pair， according to the principles of formula composition， can be effective in regulating cold and heat， smoothing the pivot， invigorating the spleen and harmonizing the stomach， resolving phlegm and dispelling dampness.. This article comprehensively reviews the research progress on the active components of COPTIDIS RHIZOMA and SCUTELLARIAE RADIX and their compound formulas for the prevention and treatment of MAFLD， aiming to provide a scientific basis for further investigation of their mechanisms， rational clinical application， and new drug development.
[1] Zhang Xiang， Lau H C， Yu Jun. Pharmacological treatment for metabolic dysfunction-associated steatotic liver disease and related disorders: Current and emerging therapeutic options [J]. Pharmacol Rev， 2025， 77(2): 100018.
[2] Li Lu， Wang Zeyu， Jiang Yong. Global incidence of NAFLD: Sets alarm bells ringing about NAFLD in China again [J]. J Hepatol， 2023， 79(4): e164-e165.
[3] Nie Wenyi， Ye Yang， Tong Hongxuan， et al. Herbal medicine as a potential treatment for non-alcoholic fatty liver disease [J]. World J Gastroenterol， 2025， 31(9): 100273.
[4] Hou Mengmeng， Gu Qi， Cui Jiawei， et al. Proportion and clinical characteristics of metabolic-associated fatty liver disease and associated liver fibrosis in an urban Chinese population [J]. Chin Med J， 2025， 138(7): 829-837.
[5] Lou Tianwen， Yang Ruixu， Fan Jiangao. The global burden of fatty liver disease: the major impact of China [J]. Hepatobiliary Surg Nutr， 2024， 13(1): 119-123.
[6] Keam S J. Resmetirom: First Approval [J]. Drugs， 2024， 84(6): 729-735.
[7] Sumida Y， Yoneda M. Current and future pharmacological therapies for NAFLD/NASH [J]. J Gastroenterol， 2018， 53(3): 362-376.
[8] Zhao Meng， Che Yanan， Gao Yan， et al. Application of multi-omics in the study of traditional Chinese medicine [J]. Front Pharmacol， 2024， 15: 1431862.
[9] Jiang Xiaofei， Tang Nannan， Liu Yuyu， et al. Integrating network analysis and pharmacokinetics to investigate the mechanisms of Danzhi Tiaozhi Decoction in metabolic-associated fatty liver disease (MAFLD) [J]. J Ethnopharmacol， 2024， 318: 117008.
[10] Zhang Xiaobo， Gao Rui， Zhou Zhen， et al. Uncovering the mechanism of Huanglian-Wuzhuyu herb pair in treating nonalcoholic steatohepatitis based on network pharmacology and experimental validation [J]. J Ethnopharmacol， 2022， 296: 115405.
[11] Tang Xiaojuan， He Min， Ren Yuan， et al. Traditional Chinese Medicine formulas-based interventions on colorectal carcinoma prevention: The efficacies， mechanisms and advantages [J]. J Ethnopharmacol， 2025， 337: 119008.
[12] Wang Shengpeng， Hu Yangyang， Tan Wen， et al. Compatibility art of traditional Chinese medicine: from the perspective of herb pairs [J]. J Ethnopharmacol， 2012， 143(2): 412-423.
[13] Zhou Honglin， Ma Cheng， Wang Cheng， et al. Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease [J]. Eur J Pharmacol， 2021， 898: 173976.
[14] Zhou Rui， Pei Xiangchang， Zhang Jingjing， et al. Research progress on chemical compositions of Coptidis Rhizoma and pharmacological effects of berberine [J]. Zhongguo Zhong Yao Za Zhi， 2020， 45(19): 4561-4573.
[15] Liao Anlu， Han Min， Chen Shujing， et al. A Comprehensive Review on Botany， Ethnopharmacology， Phytochemistry， Biosynthesis， Pharmacology， Toxicity， Quality Control and Metabolomics of Coptidis Rhizome [J]. Am J Chin Med， 2025， 53(6): 1711-1754.
[16] Zhou Mengting， Deng Ying， Liu Meichen， et al. The pharmacological activity of berberine， a review for liver protection [J]. Eur J Pharmacol， 2021， 890: 173655.
[17] Chang Wenguang， Chen Li， Hatch G M. Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies [J]. Biochem Cell Biol， 2015， 93(5): 479-486.
[18] Liao Hengfeng， Ye Jun， Gao Lili， et al. The main bioactive compounds of Scutellaria baicalensis Georgi. for alleviation of inflammatory cytokines: A comprehensive review [J]. Biomed Pharmacother， 2021， 133: 110917.
[19] Wang Ruolei， Wang Chunyan， Lu Lianheng， et al. Baicalin and baicalein in modulating tumor microenvironment for cancer treatment: A comprehensive review with future perspectives [J]. Pharmacol Res， 2024， 199: 107032.
[20] Bao Minglong， Ma Yunfei， Liang Mei， et al. Research progress on pharmacological effects and new dosage forms of baicalin [J]. Vet Med Sci， 2022， 8(6): 2773-2784.
[21] Liao Jiabao， Xie Xuehua， Wang Ning， et al. Formononetin promotes fatty acid beta-oxidation to treat non-alcoholic steatohepatitis through SIRT1/PGC-1alpha/PPARalpha pathway [J]. Phytomedicine， 2024， 124: 155285.
[22] Shang Zhi， Gao Yating， Xue Yan， et al. Shenge Formula attenuates high-fat diet-induced obesity and fatty liver via inhibiting ACOX1 [J]. Phytomedicine， 2024， 123: 155183.
[23] Zhu Xiaopeng， Bian Hua， Wang Liu， et al. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway [J]. Free Radic Biol Med， 2019， 141: 192-204.
[24] Wang Peng， Li Ruikai， Li Yuqi， et al. Berberine alleviates non-alcoholic hepatic steatosis partially by promoting SIRT1 deacetylation of CPT1A in mice [J]. Gastroenterol Rep (Oxf)， 2023， 11: goad032.
[25] Wang Yanyan， Tai Yunling， Zhao Derrick， et al. Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways [J]. Cells， 2021， 10(2).
[26] Yang Sa， Cao Shijie， Li Congyu， et al. Berberine directly targets AKR1B10 protein to modulate lipid and glucose metabolism disorders in NAFLD [J]. J Ethnopharmacol， 2024， 332: 118354.
[27] Wang Hongzhan， Wang Zhi， Wang Dingkun， et al. Berberine Attenuates Nonalcoholic Hepatic Steatosis by Regulating Lipid Droplet-Associated Proteins: In Vivo， In Vitro and Molecular Evidence [J]. J Cell Mol Med， 2025， 29(7): e70524.
[28] Gao Yanxia， Liu Jingbo， Hao Zhili， et al. Baicalin ameliorates high fat diet-induced nonalcoholic fatty liver disease in mice via adenosine monophosphate-activated protein kinase-mediated regulation of SREBP1/Nrf2/NF-kappaB signaling pathways [J]. Phytother Res， 2023， 37(6): 2405-2418.
[29] Lei Jiamin， Wang Xiaohui， Su Zheng， et al. Baicalin ameliorates high-fat diet induced MAFLD by inhibiting ERK/PPARgamma/CD36 pathway [J]. Phytomedicine， 2025， 147: 157197.
[30] Li Pan， Zhang Ruoyu， Wang Meng， et al. Baicalein Prevents Fructose-Induced Hepatic Steatosis in Rats: In the Regulation of Fatty Acid De Novo Synthesis， Fatty Acid Elongation and Fatty Acid Oxidation [J]. Front Pharmacol， 2022， 13: 917329.
[31] 王亮， 刘安宁， 李红玲， 等. 黄芩素调节PPARγ/LXRα/ABCA1信号通路干预NAFLD大鼠肝功能和胰岛素抵抗研究 [J]. 现代医学， 2023， 51(01): 17-23.
[32] Chen Jing， Liu Jie， Wang Ye， et al. Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPARalpha/AdipoR2， in vivo and in vitro [J]. Biomed Pharmacother， 2017， 91: 621-631.
[33] Li Zheng， Zhang Huixia， Li Yan， et al. Phytotherapy using blueberry leaf polyphenols to alleviate non-alcoholic fatty liver disease through improving mitochondrial function and oxidative defense [J]. Phytomedicine， 2020， 69: 153209.
[34] Yu Muyu， Alimujiang M， Hu Lili， et al. Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver [J]. Int J Biol Sci， 2021， 17(7): 1693-1707.
[35] Zhu Xinhong， Yao Ping， Liu Jingjing， et al. Baicalein attenuates impairment of hepatic lysosomal acidification induced by high fat diet via maintaining V-ATPase assembly [J]. Food Chem Toxicol， 2020， 136: 110990.
[36] Bukke V N， Moola A， SERVIDDIO G， et al. Nuclear factor erythroid 2-related factor 2-mediated signaling and metabolic associated fatty liver disease [J]. World J Gastroenterol， 2022， 28(48): 6909-6921.
[37] Pietrocola F， Bravo-San Pedro J M. Targeting Autophagy to Counteract Obesity-Associated Oxidative Stress [J]. Antioxidants (Basel)， 2021， 10(1).
[38] Yu Haifan， Duan Cuicui， Yang Zhanqing， et al. HB-EGF Ameliorates Oxidative Stress-Mediated Uterine Decidualization Damage [J]. Oxid Med Cell Longev， 2019， 2019: 6170936.
[39] Liu Wenjing， Chen Wenwen， Chen Jiaying， et al. Baicalin attenuated metabolic dysfunction-associated fatty liver disease by suppressing oxidative stress and inflammation via the p62-Keap1-Nrf2 signalling pathway in db/db mice [J]. Phytother Res， 2025， 39(4): 1663-1678.
[40] Deng Yuanjun， Tang Kairui， Chen Runsen， et al. Berberine attenuates hepatic oxidative stress in rats with non-alcoholic fatty liver disease via the Nrf2/ARE signalling pathway [J]. Exp Ther Med， 2019， 17(3): 2091-2098.
[41] 马丽， 曹昕昱， 孙永宁. 小檗碱促进巨噬细胞M2型极化改善非酒精性脂肪性肝病肝脏炎症的机制 [J]. 辽宁中医杂志， 2024， 51(12): 189-92， 240-241.
[42] Shi Huilian， Qiao Fei， Lu Weiting， et al. Baicalin improved hepatic injury of NASH by regulating NRF2/HO-1/NRLP3 pathway [J]. Eur J Pharmacol， 2022， 934: 175270.
[43] Xin Haiguang， Zhang Beibei， Wu Zhiqin， et al. Treatment with baicalein attenuates methionine-choline deficient diet-induced non-alcoholic steatohepatitis in rats [J]. Eur J Pharmacol， 2014， 738: 310-318.
[44] Jiang Guangyu， Chen Dayin， Li Wenpeng， et al. Effects of wogonoside on the inflammatory response and oxidative stress in mice with nonalcoholic fatty liver disease [J]. Pharm Biol， 2020， 58(1): 1177-1183.
[45] Kim I， Xu Wenjie， Reed J C. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities [J]. Nat Rev Drug Discov， 2008， 7(12): 1013-1030.
[46] Hotamisligil G S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease [J]. Cell， 2010， 140(6): 900-917.
[47] Perlmutter D H. Chemical chaperones: a pharmacological strategy for disorders of protein folding and trafficking [J]. Pediatr Res， 2002， 52(6): 832-836.
[48] Zhang Zhiguo， Li Bo， Meng Xiangjian， et al. Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress [J]. Sci Rep， 2016， 6: 20848.
[49] Wang Yanyan， Zhou Xxiqiao， Zhao Derrick， et al. Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes [J]. PLoS One， 2020， 15(5): e0232630.
[50] Tauil R B， Golono P T， De Lima E P， et al. Metabolic-Associated Fatty Liver Disease: The Influence of Oxidative Stress， Inflammation， Mitochondrial Dysfunctions， and the Role of Polyphenols [J]. Pharmaceuticals (Basel)， 2024， 17(10).
[51] Penas F， Mirkin G A， Vera M， et al. Treatment in vitro with PPARalpha and PPARgamma ligands drives M1-to-M2 polarization of macrophages from T. cruzi-infected mice [J]. Biochim Biophys Acta， 2015， 1852(5): 893-904.
[52] Seyedizade S S， Afshari K， Bayat S， et al. Current Status of M1 and M2 Macrophages Pathway as Drug Targets for Inflammatory Bowel Disease [J]. Arch Immunol Ther Exp (Warsz)， 2020， 68(2): 10.
[53] Li Yanwei， Sheng Qiuju， Zhang Chong， et al. STAT6 up-regulation amplifies M2 macrophage anti-inflammatory capacity through mesenchymal stem cells [J]. Int Immunopharmacol， 2021， 91: 107266.
[54] 唐彬， 宋振梅， 肖琦凡. 黄芩苷对高脂-脂肪肝模型大鼠肝脏炎症改善及炎性因子表达的影响 [J]. 青岛大学医学院学报， 2017， 53(06): 659-663， 667.
[55] Liu Jin， Yuan Yinglin， Gong Xia， et al. Baicalin and its nanoliposomes ameliorates nonalcoholic fatty liver disease via suppression of TLR4 signaling cascade in mice [J]. Int Immunopharmacol， 2020， 80: 106208.
[56] Zhang Junli， Zhang Haiming， Deng Xiaoling， et al. Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism， inflammation and fibrosis in mice [J]. Life Sci， 2018， 192: 46-54.
[57] Guan Xiulu， Shen Shiyuan， Liu Jinxia， et al. Protective effecs of baicalin magnesium on non-alcoholic steatohepatitis rats are based on inhibiting NLRP3/Caspase-1/IL-1beta signaling pathway [J]. BMC Complement Med Ther， 2023， 23(1): 72.
[58] Guo Chunyu， Li Qingjun， Chen Rihong， et al. Baicalein alleviates non-alcoholic fatty liver disease in mice by ameliorating intestinal barrier dysfunction [J]. Food Funct， 2023， 14(4): 2138-2148.
[59] Wu T R， Lin ChuanSheng， Chang C J， et al. Gut commensal Parabacteroides goldsteinii plays a predominant role in the anti-obesity effects of polysaccharides isolated from Hirsutella sinensis [J]. Gut， 2019， 68(2): 248-262.
[60] Aron-Wisnewsky J， Vigliotti C， Witjes J， et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders [J]. Nat Rev Gastroenterol Hepatol， 2020， 17(5): 279-297.
[61] Fan Yue， Liu Yinhui， Shao Chenyi， et al. Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insights into the Synergy of Probiotic-Fermented Herbal Bioactives [J]. Int J Mol Sci， 2025， 26(12).
[62] Katsiki N， Mikhailidis D P， MANTZOROS C S. Non-alcoholic fatty liver disease and dyslipidemia: An update [J]. Metabolism， 2016， 65(8): 1109-1123.
[63] Yang Sa， Cao Shijie， Li Congyu， et al. Berberrubine， a Main Metabolite of Berberine， Alleviates Non-Alcoholic Fatty Liver Disease via Modulating Glucose and Lipid Metabolism and Restoring Gut Microbiota [J]. Front Pharmacol， 2022， 13: 913378.
[64] Li Ping， Hu Jianran， Zhao Hongmei， et al. Multi-Omics Reveals Inhibitory Effect of Baicalein on Non-Alcoholic Fatty Liver Disease in Mice [J]. Front Pharmacol， 2022， 13: 925349.
[65] Qian Hui， Chao Xiaojuan， Williams J， et al. Autophagy in liver diseases: A review [J]. Mol Aspects Med， 2021， 82: 100973.
[66] Chu Qiang， Zhang Shuang， Chen Meng， et al. Cherry Anthocyanins Regulate NAFLD by Promoting Autophagy Pathway [J]. Oxid Med Cell Longev， 2019， 2019: 4825949.
[67] Shen Bingyu， Wang Yeling， Cheng Jiaqi， et al. Pterostilbene alleviated NAFLD via AMPK/mTOR signaling pathways and autophagy by promoting Nrf2 [J]. Phytomedicine， 2023， 109: 154561.
[68] He Qin， Mei Dan， Sha Sha， et al. ERK-dependent mTOR pathway is involved in berberine-induced autophagy in hepatic steatosis [J]. J Mol Endocrinol， 2016， 57(4): 251-260.
[69] Zhong Huahua， Hu Shaojie， Yu Bo， et al. Apoptosis in the aging liver [J]. Oncotarget， 2017， 8(60): 102640-102652.
[70] Wang Peipei， Huang Xia， Yang Meiwen， et al. Effects of non-drug treatment on liver cells apoptosis during hepatic ischemia-reperfusion injury [J]. Life Sci， 2021， 275: 119321.
[71] Dong Qingfu， Bao Haolin， Wang Jiangang， et al. Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies [J]. Front Med (Lausanne)， 2023， 10: 1120621.
[72] Veskovic M， Pejovic M， Sutulovic N， et al. Exploring Fibrosis Pathophysiology in Lean and Obese Metabolic-Associated Fatty Liver Disease: An In-Depth Comparison [J]. Int J Mol Sci， 2024， 25(13).
[73] Jiang Yuanye， Zhang Jiaqi， Liu Wangzhenzu， et al. Scutellariae Radix and Coptidis Rhizoma improve NAFLD via regulation of SIRT6/ACSL5 pathway and SCD1 [J]. Journal of Ethnopharmacology， 2025， 348: 119834.
[74] 刘王振祖， 钱晓婧， 张家祺， 等. 基于脂质组学研究黄芩-黄连药对的降脂作用 [J]. 中国中药杂志， 2023， 48(24): 6711-6720.
[75] 魏悦. 基于氧化应激及炎症探究黄芩黄连药对改善非酒精性脂肪性肝炎的作用机制 [D]; 江西中医药大学， 2022: 106.
[76] 薛亚楠. 基于FXR/CYP7A1通路探究黄芩黄连药对改善非酒精性脂肪性肝病的作用机制 [D]; 江西中医药大学， 2021:68.
[77] Zhang Yani， Wang Jiahua， Li Xuetao， et al. Huanglian Jiedu Decoction improves the"central-peripheral"inflammatory microenvironment and enhances the cognitive function of APP/PS1 mice by inhibiting the activation of NLRP3 inflammasome mediated by gut microbiota [J]. Chin Med， 2025， 20(1): 123.
[78] Zheng Renyuan， Shi Shenggan， Zhang Qin， et al. Molecular mechanisms of Huanglian Jiedu decoction in treating Alzheimer's disease by regulating microbiome via network pharmacology and molecular docking analysis [J]. Front Cell Infect Microbiol， 2023， 13: 1140945.
[79] Tian Ruimin， Liu Xianfeng， Jing Lijia， et al. Huang-Lian-Jie-Du decoction attenuates cognitive dysfunction of rats with type 2 diabetes by regulating autophagy and NLRP3 inflammasome activation [J]. J Ethnopharmacol， 2022， 292: 115196.
[80] Dong Shu， Xu Panling， Yang Peiwen et al. "Huanglianjiedu Decoction" Against Pancreatic Adenocarcinoma Proliferation of by Downregulating the PI3K/AKT/mTOR and MAPK/ERK1/2 Signaling Pathways [J]. J Evid Based Integr Med， 2024， 29: 2515690X241291381.
[81] Zheng Anli， Lin Mengyu， Zheng Jixian， et al. Huanglian Jiedu Decoction Alleviates Metabolic-Associated Fatty Liver Disease in vivo and in vitro via IRE1alpha/XBP1s Signaling Pathway [J]. Chin J Integr Med， 2026.
[82] 马雅銮， 李彤， 王蓓蓓， 等. 黄连解毒汤对高脂血症小鼠肝脏保护作用的观察 [J]. 中国中西医结合杂志， 2013， 33(08): 1107-1111.
[83] 张霞， 李云静， 李刚， 等. 黄连解毒汤对非酒精性脂肪性肝病患者的治疗作用 [J]. 辽宁中医药大学学报， 2013， 15(10): 73-75.
[84] Shu Xiangbing， Cao Ying， Wu Yan， et al. Gegen-Qinlian decoction alleviates metabolic dysfunction-associated steatohepatitis by modulating the microbiota-bile acid axis in mice [J]. J Ethnopharmacol， 2025， 347: 119719.
[85] Zhang Changhua， Xiao Qin， Sheng Junqing， et al. Gegen Qinlian Decoction abates nonalcoholic steatohepatitis associated liver injuries via anti-oxidative stress and anti-inflammatory response involved inhibition of toll-like receptor 4 signaling pathways [J]. Biomed Pharmacother， 2020， 126: 110076.
[86] Guo Yi， Ding Panghua， Liu Lijuan， et al. Gegen Qinlian Decoction Attenuates High-Fat Diet-Induced Steatohepatitis in Rats via Gut Microbiota [J]. Evid Based Complement Alternat Med， 2018， 2018: 7370891.
[87] 骆倩， 罗涛， 宋针珍， 等. 基于Nrf2/SLC7A11/GPX4通路探讨葛根芩连汤通过抑制铁死亡改善非酒精性脂肪性肝病作用机制 [J]. 中国比较医学杂志， 2025， 35(02): 72-84.
[88] 张超云， 费娜， 郝鹏飞， 等. 基于内质网应激探讨葛根芩连汤对非酒精性脂肪肝大鼠PERK-eIF2α通路的影响 [J]. 中国医院药学杂志， 2024， 44(04): 384-390.
[89] Ying Yuqi， Zhang Haitao， Yu Dian， et al. Gegen Qinlian Decoction Ameliorates Nonalcoholic Fatty Liver Disease in Rats via Oxidative Stress， Inflammation， and the NLRP3 Signal Axis [J]. Evid Based Complement Alternat Med， 2021， 2021: 6659445.
[90] Wang Yi， Zhao Tong， Huang Chuyue， et al. Effect and mechanism of Banxia Xiexin decoction in colorectal cancer: A network pharmacology approach [J]. Phytomedicine， 2024， 123: 155174.
[91] 张会凯. 半夏泻心汤治疗糖尿病合并非酒精性脂肪肝的临床研究 [J]. 云南中医中药杂志， 2024， 45(01): 63-65.
[92] 绽永华， 王学红， 王芳. 半夏泻心汤加减对非酒精性脂肪肝的临床疗效及对胰岛素抵抗的调节效果观察 [J]. 中国实验方剂学杂志， 2021， 27(03): 117-122.
[93] 张会凯. 半夏泻心汤治疗非酒精性脂肪肝病的临床研究 [J]. 内蒙古中医药， 2023， 42(11): 16-18.
[94] Luo Yiting， Wu Jin， Zhu Fangyuan， et al. Gancao Xiexin Decoction Ameliorates Ulcerative Colitis in Mice via Modulating Gut Microbiota and Metabolites. Drug Des Devel Ther. 2022;16:1383-1405.
[95] 宋文佳. 甘草泻心汤在肿瘤治疗中的应用 [J]. 中国中医药现代远程教育， 2019， 17(08): 52-54.
[96] 吴家辉， 谭祖心， 邓倩. 甘草泻心汤联合多烯磷酸胆碱胶囊治疗非酒精性脂肪肝的疗效观察 [J]. 广东医科大学学报， 2020， 38(01): 53-56.
[97] 淡丽娟， 刘雨樵， 郝彦伟， 等. 吴氏泻心汤加减方通过抑制TLR4/NF-κB通路改善小鼠非酒精性脂肪性肝病的炎症反应 [J]. 中国中药杂志， 2026， 51(02): 533-542.
[98] Rad S Z K， Rameshrad M， Hosseinzadeh H. Toxicology effects of Berberis vulgaris (barberry) and its active constituent， berberine: a review [J]. Iran J Basic Med Sci， 2017， 20(5): 516-529.
基本信息:
DOI：10.13412/j.cnki.zyyl.20260930.001
中图分类号:R285;R259
引用信息:
[1]淡丽娟,王天媛,游晓洁,等.黄连-黄芩活性成分及方剂配伍治疗代谢相关脂肪性肝病的研究进展[J].中药药理与临床().DOI:10.13412/j.cnki.zyyl.20260930.001.
基金信息:
国家自然科学青年基金项目（编号：82505222）; 四川省青年基金项目（编号：2026NSFSC1883、2025ZNSFSC1795、2025ZNSFSC0619）; 四川省中医药管理局项目（编号：2024MS390）; 成都市卫生健康委员会联合创新专项（编号：WXLH202402052）; 成都中医药大学青基人才专项（编号：QJRC2024002）;成都中医药大学院校联合项目（编号：XYLH202501012）
2026-09-30
2026-09-30
2026-09-30